BeOne Medicines Ltd.
BeOne Medicines Ltd. (ONC) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ONC · as of Jun 8, 2026
Key Statistics
Explore BeOne Medicines Ltd. Data
onc stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 14 · Buy rate: 92.9%
The ONC analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month price target is $399.11, representing +47.76% upside from the current price of $270.10.
Competitors & Peers
onc competitorsONC
A
ALC
GEHC
HUM
INSMStock Performance
Full HistoryAbout BeOne Medicines Ltd.
BeOne Medicines Ltd. BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambr…
what is beone medicines ltd. · onc stock overview · beone medicines ltd. company profile · who is beone medicines ltd. ceo · onc NASDAQ · beone medicines ltd. headquarters · beone medicines ltd. business segments
About Stock Overview & Key Data
BeOne Medicines Ltd. (ONC) is a Healthcare company in the Medical - Pharmaceuticals industry, listed on NASDAQ since Feb 2, 2016. As of the latest trading session, ONC stock price is $270.10, with a market capitalization of $28.9B. The stock has returned +2.40% over the past 12 months and -11.10% year-to-date.
According to 14 Wall Street analysts, the consensus rating for BeOne Medicines Ltd. stock is Buy, with an average 12-month price target of $399.11. In fiscal year 2025, BeOne Medicines Ltd. reported revenue of $5.3B and net income of $286.9M. For detailed data — including BeOne Medicines Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, BeOne Medicines Ltd. (ONC) stock price is $270.10. The stock is traded on NASDAQ under the ticker symbol ONC. The 52-week range is $239.25 – $385.22.